» Articles » PMID: 36086906

N6-methyladenosine-modified HOTAIRM1 Promotes Vasculogenic Mimicry Formation in Glioma

Overview
Journal Cancer Sci
Specialty Oncology
Date 2022 Sep 10
PMID 36086906
Authors
Affiliations
Soon will be listed here.
Abstract

Vasculogenic mimicry (VM) has been reported to accelerate angiogenesis in malignant tumors, yet the mechanism underlying VM has not been fully elucidated. N6-methyladenosine (m6A) mainly modulates mRNA fate and affects multiple tumorigenesis. Here, we aimed to investigate m6A-modified HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) in the regulation of glioma-associated VM formation. Gene expression was analyzed by quantitative RT-PCR. Cell viability, metastases, and VM formation capacity were determined by CCK-8, migration and invasion, as well as tube formation assays, respectively. The function and mechanisms of m6A-modified HOTAIRM1 were defined through liquid chromatography-tandem mass spectrometry m6A quantification, methylated RNA immunoprecipitation sequencing, RNA stability assays, and RNA pull-down experiments. A glioma xenograft mouse model was further established for VM evaluation in vivo. The results showed that HOTAIRM1, methyltransferase-like 3 (METTL3), and insulin-like growth factor binding protein 2 (IGFBP2) were upregulated in glioma tissues and cell lines. HOTAIRM1 functions as an oncogene in glioma progression; however, knockdown of HOTAIRM1 significantly reduced cell viability, migration, invasion, and VM formation. Notably, METTL3-dependent m6A modification enhanced HOTAIRM1 mRNA stability, whereas knockdown of METTL3 deficiency significantly suppressed VM in glioma. Moreover, HOTAIRM1 was found to bind IGFBP2, and HOTAIRM1 deficiency blocked glioma progression and VM formation in vivo. Our results indicated that METTL3-dependent m6A-modified HOTAIRM1 promoted VM formation in glioma.

Citing Articles

The role of N6-methyladenosine modification in tumor angiogenesis.

Qin L, Zeng X, Qiu X, Chen X, Liu S Front Oncol. 2024; 14:1467850.

PMID: 39691597 PMC: 11649548. DOI: 10.3389/fonc.2024.1467850.


LncRNA HOTAIRM1 promotes radioresistance in nasopharyngeal carcinoma by modulating FTO acetylation-dependent alternative splicing of CD44.

Mi J, Wang Y, He S, Qin X, Li Z, Zhang T Neoplasia. 2024; 56:101034.

PMID: 39128424 PMC: 11367117. DOI: 10.1016/j.neo.2024.101034.


Role of N6-methyladenosine in tumor neovascularization.

Zhao L, Li Q, Zhou T, Liu X, Guo J, Fang Q Cell Death Dis. 2024; 15(8):563.

PMID: 39098905 PMC: 11298539. DOI: 10.1038/s41419-024-06931-z.


The role of m6A in angiogenesis and vascular diseases.

Chen K, Li W, Li X iScience. 2024; 27(7):110082.

PMID: 39055919 PMC: 11269316. DOI: 10.1016/j.isci.2024.110082.


Characterization of m6A methylation modifications in gastric cancer.

Yin W, Huo Z, Zuo J, Wang H, Chen B, Zhou L Aging (Albany NY). 2024; 16(1):89-105.

PMID: 38206646 PMC: 10817395. DOI: 10.18632/aging.205341.


References
1.
Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

2.
Wu Z, Lin Y, Wei N . N6-methyladenosine-modified HOTAIRM1 promotes vasculogenic mimicry formation in glioma. Cancer Sci. 2022; 114(1):129-141. PMC: 9807531. DOI: 10.1111/cas.15578. View

3.
Lin Y, Guo L, Yan F, Dou Z, Yu Q, Chen G . Long non-coding RNA HOTAIRM1 promotes proliferation and inhibits apoptosis of glioma cells by regulating the miR-873-5p/ZEB2 axis. Chin Med J (Engl). 2020; 133(2):174-182. PMC: 7028173. DOI: 10.1097/CM9.0000000000000615. View

4.
Fu Y, Dominissini D, Rechavi G, He C . Gene expression regulation mediated through reversible m⁶A RNA methylation. Nat Rev Genet. 2014; 15(5):293-306. DOI: 10.1038/nrg3724. View

5.
Moore L, Holmes K, Smith S, Wu Y, Tchougounova E, Uhrbom L . IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A. 2009; 106(39):16675-9. PMC: 2757856. DOI: 10.1073/pnas.0900807106. View